Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of navitoclax when given
together with sorafenib tosylate in treating patients with solid tumors that have returned
(relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.